Productivity costs and medical costs among working patients with knee osteoarthritis

Arthritis Care and Research

Volumn 64, Issue 6, 2012, Pages 853-861

  Hermans, Job ^a   Koopmanschap, Marc A ^b   Bierma Zeinstra, Sita M A ^a   Van Linge, Joost H ^c   Verhaar, Jan A N ^a   Reijman, Max ^a   Burdorf, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; HYALURONIC ACID;

ABSENTEEISM; ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CONSERVATIVE TREATMENT; COST BENEFIT ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; EMPLOYMENT; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; JOB PERFORMANCE; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; REST; ADOLESCENT; ECONOMICS; INTRAARTICULAR DRUG ADMINISTRATION; MIDDLE AGED; NETHERLANDS; OCCUPATIONAL HEALTH; ORGANIZATION AND MANAGEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; COST-BENEFIT ANALYSIS; EFFICIENCY, ORGANIZATIONAL; FEMALE; HEALTH CARE COSTS; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MALE; MIDDLE AGED; NETHERLANDS; OCCUPATIONAL HEALTH; OSTEOARTHRITIS, KNEE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84863213420     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21617     Document Type: Article

References (51)

1. Buckwalter JA, Saltzman C, Brown T. The impact of osteoarthritis: implications for research. Clin Orthop Relat Res 2004;427 Suppl: S6-15.
2. CDC. Estimated number of US population with physicandiagnosed osteoarthritis. Atlanta: Centers for Disease Control and Prevention; 1990.
3. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646-56.
4. Dunlop DD, Manheim LM, Yelin EH, Song J, Chang RW. The costs of arthritis. Arthritis Rheum 2003;49:101-3.
5. March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. Baillieres Clin Rheumatol 1997;11:817-34.
6. Reginster JY. The prevalence and burden of arthritis. Rheumatology (Oxford) 2002;41 Suppl 1:3-6.
7. Drummond MF, Sculpher JM, Torrance GW, O'Brien BJ, Stoddart GL. Cost analysis. In: Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 55-102.
8. Maetzel A, Li LC, Pencharz J, Tomlinson G, Bombardier C. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis 2004;63:395-401.
9. Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 2006;33:1152-8.
10. Aronsson G, Gustafsson K. Sickness presenteeism: prevalence, attendance-pressure factors, and an outline of a model for research. J Occup Environ Med 2005;47:958-66.
11. Brouwer WB, Koopmanschap MA, Rutten FF. Productivity losses without absence: measurement validation and empirical evidence. Health Policy 1999;48:13-27.
12. Schultz AB, Edington DW. Employee health and presenteeism: a systematic review. J Occup Rehabil 2007;17:547-79.
13. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J Rheumatol 1997;24:43-8.
14. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Med Care 2006;44:304-10.
15. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290:2443-54.
16. Van den Heuvel SG, Ijmker S, Blatter BM, de Korte EM. Loss of productivity due to neck/shoulder symptoms and hand/arm symptoms: results from the PROMO study. J Occup Rehabil 2007;17:370-82.
17. Kramer JS, Yelin EH, Epstein WV. Social and economic impacts of four musculoskeletal conditions: a study using national community-based data. Arthritis Rheum 1983;26:901-7.
18. Bernaards CM, Proper KI, Hildebrandt VH. Physical activity, cardiorespiratory fitness, and body mass index in relationship to work productivity and sickness absence in computer workers with preexisting neck and upper limb symptoms. J Occup Environ Med 2007;49:633-40.
19. Burton WN, Chen CY, Schultz AB, Edington DW. The economic costs associated with body mass index in a workplace. J Occup Environ Med 1998;40:786-92.
20. Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The role of health risk factors and disease on worker productivity. J Occup Environ Med 1999;41:863-77.
21. Gates DM, Succop P, Brehm BJ, Gillespie GL, Sommers BD. Obesity and presenteeism: the impact of body mass index on workplace productivity. J Occup Environ Med 2008;50:39-45.
22. Van den Heuvel SG, Geuskens GA, Hooftman WE, Koppes LL, van den Bossche SN. Productivity loss at work; health-related and work-related factors. J Occup Rehabil 2010;20:331-9.
23. Alavinia SM, de Boer AG, van Duivenbooden JC, Frings-Dresen MH, Burdorf A. Determinants of work ability and its predictive value for disability. Occup Med (Lond) 2009;59:32-7.
24. Jensen LK. Knee osteoarthritis: influence of work involving heavy lifting, kneeling, climbing stairs or ladders, or kneeling/squatting combined with heavy lifting. Occup Environ Med 2008;65:72-89.
25. Elders LA, Burdorf A. Interrelations of risk factors and low back pain in scaffolders. Occup Environ Med 2001;58:597-603.
26. IJzelenberg W, Burdorf A. Risk factors for musculoskeletal symptoms and ensuing health care use and sick leave. Spine (Phila Pa 1976) 2005;30:1550-6.
27. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
28. Van Meurs JB, Bierma-Zeinstra SM, Uitterlinden AG. Osteoarthritis. In: National compass public health. Bilthoven (The Netherlands): RIVM (Dutch State Institute of Public Health and Environment); 2009. URL: http://www. nationaalkompas.nl/gezondheid-en-ziekte/ziekten-en-aandoeningen/ bewegingsstelsel-en-bindweefsel/artrose/.
29. Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573-7.
30. Gabriel SE, Crowson CS, Campion ME, O'Fallon WM. Direct medical costs unique to people with arthritis. J Rheumatol 1997;24:719-25.
31. Pincus T, Mitchell JM, Burkhauser RV. Substantial work disability and earnings losses in individuals less than age 65 with osteoarthritis: comparisons with rheumatoid arthritis. J Clin Epidemiol 1989;42:449-57.
32. Koopmanschap MA. PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studies. Expert Rev Pharmacoecon Outcomes Res 2005;5:23-8.
33. Meerding WJ, IJzelenberg W, Koopmanschap MA, Severens JL, Burdorf A. Health problems lead to considerable productivity loss at work among workers with high physical load jobs. J Clin Epidemiol 2005;58:517-23.
34. Hakkaart-Van Rooijen L, Tan SS, Bouwmans CA. Manual for costing research, methods and standard prices for economic evaluatons in healthcare. Amstelveen: CVZ (Health Care Insurance Counsel); 2010.
35. Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990;17:1022-4.
36. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
37. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
38. De Groot IB, Favejee MM, Reijman M, Verhaar JA, Terwee CB. The Dutch version of the Knee Injury and Osteoarthritis Outcome Score: a validation study. Health Qual Life Outcomes 2008;6:16.
39. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and Osteoarthritis Outcome Score (KOOS): development of a self-administered outcome measure. J Orthop Sports Phys Ther 1998;28:88-96.
40. Karasek R, Baker D, Marxer F, Ahlbom A, Theorell T. Job decision latitude, job demands, and cardiovascular disease: a prospective study of Swedish men. Am J Public Health 1981;71:694-705.
41. Van den Berg TI, Robroek SJ, Plat JF, Koopmanschap MA, Burdorf A. The importance of job control for workers with decreased work ability to remain productive at work. Int Arch Occup Environ Health 2011;84:705-12.
42. Statistical Package for Social Sciences (SPSS). New York: IBM; 2009.
43. Leardini G, Salaffi F, Caporali R, Canesi B, Rovati L, Montanelli R. Direct and indirect costs of osteoarthritis of the knee. Clin Exp Rheumatol 2004;22:699-706.
44. Dibonaventura MD, Gupta S, McDonald M, Sadosky A. Evaluating the health and economic impact of osteoarthritis pain in the workforce: results from the National Health and Wellness Survey. BMC Musculoskelet Disord 2011;12:83.
45. Ricci JA, Stewart WF, Chee E, Leotta C, Foley K, Hochberg MC. Pain exacerbation as a major source of lost productive time in US workers with arthritis. Arthritis Rheum 2005;53:673-81.
46. Hoeijenbos M, Bekkering T, Lamers L, Hendriks E, van Tulder M, Koopmanschap M. Cost-effectiveness of an active implementation strategy for the Dutch physiotherapy guideline for low back pain. Health Policy 2005;75:85-98.
47. Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, et al. Costs and quality of life in multiple sclerosis in The Netherlands. Eur J Health Econ 2006;7 Suppl 2:S55-64.
48. Rutten-van Molken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics 2007;25:695-711.
49. Van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9.
50. Van den Hout WB, Peul WC, Koes BW, Brand R, Kievit J, Thomeer RT, et al. Prolonged conservative care versus early surgery in patients with sciatica from lumbar disc herniation: cost utility analysis alongside a randomised controlled trial. BMJ 2008;336:1351-4.
51. Severens JL, Mulder J, Laheij RJ, Verbeek AL. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Soc Sci Med 2000;51:243-9.